Skip to content
Review Open access

Nipah virus vaccine development: current platforms, preclinical evidence, and clinical translation

Sep 2026 · Frontiers in Drug Discovery · 1 citation · 175 references

TL;DR

Overall, continued advances in translational vaccinology, computational vaccine design, and global preparedness may accelerate the development of NiV vaccines.

Abstract

Nipah virus (NiV) is a highly pathogenic zoonotic member of the genus Henipavirus . Due to its high fatality rate and increasing evidence of human-to-human transmission, it remains a major global health concern. Since its first emergence during the Malaysian outbreak, NiV has caused repeated outbreaks across South and Southeast Asia, particularly in Bangladesh and India. The absence of licensed vaccines or specific antiviral therapies has intensified the need for global efforts toward vaccine development and outbreak preparedness. This review aims to provide a comprehensive overview of the current status of NiV vaccine research, with emphasis on recent advances in vaccine platforms in preclinical and clinical trials. Relevant literature related to NiV epidemiology, viral pathogenesis, immunobiology, and vaccine development was comprehensively reviewed to summarize current knowledge and recent advances in vaccine development. Major vaccine approaches critically evaluated for their immunogenicity and protective response in this study include recombinant soluble glycoprotein subunit vaccines, viral-vectored vaccines, mRNA-based vaccines, DNA vaccines, virus-like particles, and nanoparticle-based systems. Recent advances in immunoinformatic-guided multi-epitope vaccine design and rapid-response vaccine manufacturing strategies were also assessed in the context of emerging pandemic preparedness initiatives such as Coalition for Epidemic Preparedness Innovations (CEPI) “100 Days Mission”. Current evidence indicates that several NiV vaccine candidates, like subunit, viral-vectored, and mRNA-based platforms, have progressed from experimental to early-phase clinical evaluation. However, the absence of validated immune correlates of protection, limited outbreak predictability, difficulties in conventional efficacy trials, and antigenic variability pose major challenges in outbreak-prone regions. Overall, continued advances in translational vaccinology, computational vaccine design, and global preparedness may accelerate the development of NiV vaccines.

Read PDF

Similar papers

Review Open access Oct 2026

Advances in Bluetongue Virus Antigenicity and Vaccine Strategies: Progress and Perspectives

Simple Summary This review elucidates the antigenic architecture of Bluetongue virus (BTV) and the ensuing immune responses. It critically evaluates the advantages and disadvantages of conventional vaccines relative to emerging vaccine platforms. Furthermore, it underscores the imperative for future research to develop...

Xin-Yi Li, Zheng-Hao Ye, Ni-Jing Lei et al. · 0 citations
Review Open access Sep 2026

Advances and challenges in avian influenza vaccines: From conventional approaches to next-generation strategies

Background Avian influenza viruses (AIVs), particularly highly pathogenic H5 and H7 viruses, pose major threats to poultry production, food security, international trade, and public health. Vaccination is an important component of AIV control; however, antigenic evolution, incomplete reduction of viral shedding, and ch...

M. Nazari, M. Mehrazar · 0 citations
Review Open access Aug 2026

Advances in therapeutics and vaccines for Marburg virus disease: challenges and future directions.

The human monoclonal antibody MR191N provides complete post-exposure protection in non-human primates and necessitates adaptive trial designs, expanded diagnostic models, and synergistic combination therapies to address MVD.

V. Kandi, F. Branda, Mohammed Alissa et al. · 0 citations
Review Open access Sep 2026

Current challenges emerging strategies and future directions in vaccine development for haemorrhagic septicemia

Haemorrhagic septicemia (HS), caused by Pasteurella multocida serotypes B:2 and E:2, remains a major infectious disease of cattle and buffalo in endemic regions of Asia and Africa and has increasingly been recognized as a threat to susceptible wildlife. Despite decades of vaccination, recurrent outbreaks continue, high...

R. Raj, Ashwani Kumar Sharma · 0 citations
Review Sep 2026

mRNA-Based Vaccine Platforms Targeting Plasmodium falciparum Circumsporozoite Protein: A Comprehensive Review

Malaria remains a major global health burden, with Plasmodium falciparum responsible for the majority of severe disease and mortality, particularly in sub-Saharan Africa, as consistently reported by the World Health Organization. Although recent vaccine approvals marked significant progress, currently deployed protein-...

Mutebi Mark · 0 citations
Review Open access Aug 2026

Current state of monkeypox vaccine development

The aim of this review is to summarize the evidence on contemporary candidate vaccines against monkeypox developed using different approaches, and addresses both classical live attenuated vaccinia virus-based vaccines, previously approved for prevention of monkeypox, and vaccines being developed using recombinant techn...

A. A. Sulgin, A. Ilyichev, M. Azaev et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.